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Abstract: Purpose We aimed to compare treatment results in and outside of a randomized trial and to
confirm factors influencing outcome in a large retrospective cohort of nonmetastatic medulloblastoma
treated in Austria, Switzerland and Germany. Methods and Materials Patients with nonmetastatic
medulloblastoma (n = 382) aged 4 to 21 years and primary neurosurgical resection between 2001 and
2011 were assessed. Between 2001 and 2006, 176 of these patients (46.1%) were included in the randomized
HIT SIOP PNET 4 trial. From 2001 to 2011 an additional 206 patients were registered to the HIT 2000
study center and underwent the identical central review program. Three different radiation therapy
protocols were applied. Genetically defined tumor entity (former molecular subgroup) was available for
157 patients. Results Median follow-up time was 7.3 (range, 0.09-13.86) years. There was no difference
between HIT SIOP PNET 4 trial patients and observational patients outside the randomized trial, with
7 years progression-free survival rates (PFS) of 79.5% ± 3.1% versus 78.7% ± 3.1% (P = .62). On
univariate analysis, the time interval between surgery and irradiation (฀ 48 days vs ฀ 49 days) showed
a strong trend to affect PFS (80.4% ± 2.2% vs 64.6% ± 9.1%; P = .052). Furthermore, histologically
and genetically defined tumor entities and the extent of postoperative residual tumor influenced PFS.
On multivariate analyses, a genetically defined tumor entity wingless-related integration site-activated vs
non-wingless-related integration site/non-SHH, group 3 hazard ratio, 5.49; P = .014) and time interval
between surgery and irradiation (hazard ratio, 2.2; P = .018) were confirmed as independent risk factors.
Conclusions Using a centralized review program and risk-stratified therapy for all patients registered
to the study center, outcome was identical for patients with nonmetastatic medulloblastoma treated on
and off the randomized HIT SIOP PNET 4 trial. The prognostic values of prolonged time to RT and
genetically defined tumor entity were confirmed.
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Abstract
Purpose: We aimed to compare treatment results in and outside of a randomized trial and to confirm factors influencing outcome in a
large retrospective cohort of nonmetastatic medulloblastoma treated in Austria, Switzerland and Germany.
Methods and Materials: Patients with nonmetastatic medulloblastoma (n Z 382) aged 4 to 21 years and primary neurosurgical
resection between 2001 and 2011 were assessed. Between 2001 and 2006, 176 of these patients (46.1%) were included in the ran-
domized HIT SIOP PNET 4 trial. From 2001 to 2011 an additional 206 patients were registered to the HIT 2000 study center and
underwent the identical central review program. Three different radiation therapy protocols were applied. Genetically defined tumor
entity (former molecular subgroup) was available for 157 patients.
Results: Median follow-up time was 7.3 (range, 0.09-13.86) years. There was no difference between HIT SIOP PNET 4 trial
patients and observational patients outside the randomized trial, with 7 years progression-free survival rates (PFS) of 79.5%  3.1%
versus 78.7%  3.1% (P Z .62). On univariate analysis, the time interval between surgery and irradiation ( 48 days vs  49 days)
showed a strong trend to affect PFS (80.4%  2.2% vs 64.6%  9.1%; PZ .052). Furthermore, histologically and genetically defined
tumor entities and the extent of postoperative residual tumor influenced PFS. On multivariate analyses, a genetically defined tumor
entity wingless-related integration site-activated vs non-wingless-related integration site/non-SHH, group 3 hazard ratio, 5.49; P Z
.014) and time interval between surgery and irradiation (hazard ratio, 2.2; P Z .018) were confirmed as independent risk factors.
Conclusions: Using a centralized review program and risk-stratified therapy for all patients registered to the study center, outcome was
identical for patients with nonmetastatic medulloblastoma treated on and off the randomized HIT SIOP PNET 4 trial. The prognostic
values of prolonged time to RT and genetically defined tumor entity were confirmed.
 2020 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The HIT (German acronym for brain tumor) treatment
network is a joint working group for childhood brain
tumors of the German Society for Pediatric Oncology and
Hematology (GPOH). It is a unique collaborative project
of German-speaking countries (Germany, Austria and
Switzerland) to offer central review and treatment
recommendations in dedicated central review institutions.
The aims are to perform research projects and clinical
trials but also to improve treatment and outcome for all
patients even outside randomized trials.
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One important research project was the HIT 2000 trial,
which among others included patients with nonmetastatic
medulloblastoma (MB) aged 4 to 21 years (HIT AB4
stratum). Parts of this stratum were the German cohort of
the HIT SIOP PNET 4 trial (ClinicalTrials.gov identifier:
NCT01351870). Patients not eligible for the HIT SIOP
PNET 4 trial could be registered as observational patients
and receive centrally reviewed and risk-stratified
treatment.
Protocols combined surgery, craniospinal irradiation
(CSI) with a boost to the posterior fossa or the tumor site,
and chemotherapy.1,2 Various factors influencing
outcome in patients with MB have been identified, for
example, histology or residual tumor. Others are still a
matter of debate, for example, time from surgery to
radiation therapy (RT).3,4-9 Moreover, definition of
histologically and genetically defined MB entities (former
molecular subgroups) in the 2016 World Health
Organization (WHO) classification of central nervous
system tumors changed our view on MB.10-13
The primary purpose of this study was to compare
outcomes of patients with nonmetastatic MB treated with
upfront RT during the HIT 2000 protocol era included in
the randomized HIT SIOP PNET 4 trial with patients not
included in the trial. We sought to achieve an equivalent
outcome for patients treated outside the trial by using a
centralized review program for the nontrial observational
patients. Furthermore, we intended to confirm prognostic




Between 2001 and 2011, 419 patients were registered
to the HIT 2000 trial. According to inclusion criteria as
specified in Figure 1, 382 patients were selected. The
cohort does not match with the standard risk group as
used today, because patients with high-risk features
(residual disease > 1.5 cm2, large cell anaplastic) were
also included.14 The cohort was divided into 2 treatment
eras, the HIT SIOP PNET 4 era (2001-2006) and the era
beyond the trial (2007-2011) and according to
participation in the trial as shown in the consort diagram
(Fig 1). Central review of pre- and postoperative magnetic
resonance imaging (MRI), spinal MRI, and cerebrospinal
fluid cytology was offered for all patients either upfront or
retrospectively and was completely available for 91.1% of
419 patients registered to HIT 2000
Inclusion criteria:
- Initial tumor resection between 01.01.2001 and 31.12.2011
- Locally confirmed medulloblastoma
- Non metastatic disease
- Age at surgery between 4-21 years
- Informed consent
- Planned immediate postoperative radiotherapy
Excluded patients:
- 10 no central review of histology
- 1 ependymoma at central review
- 1 metastatic reccurence before start of RT
- 1 death before start of RT
- 23 chemotherapy before start of RT
- 1 informed consent withdrawn
SIOP PNET 4 trial era
2001-2006 (n=233)
SIOP PNET 4 trial patients
(n=176)







Figure 1 Consort diagram of the present study.
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patients. Central review of histopathology according to
the 2007 WHO classification was available for all patients
and was reclassified for patients diagnosed before 2007.15
The HIT 2000 trial was approved by the ethics
committee Wuerzburg. All patients or their legal
representatives signed informed consent before
registration to the HIT 2000 trial.
Adjuvant treatment
All patients received postoperative RT according to 1
of these protocols:
Hyperfractionated RT (HFRT)
Total craniospinal dose 36 Gy, followed by a boost to
the whole posterior fossa to 60 Gy and further boost to
68 Gy to the tumor bed in 2-daily, 10-weekly fractions of
1.0 Gy (34 days with RT, RT duration without
interruptions 46-48 days).
Standard fractionated reduced dose craniospinal RT
(STRT23.4)
Total craniospinal dose 23.4 Gy followed by a boost to
the posterior fossa to 54.0 Gy in 1-daily, 5-weekly
fractions of 1.8 Gy (30 fractions, RT duration without
interruptions 40-42 days).
Standard fractionated high dose craniospinal RT
(STRT35.2)
Total craniospinal dose of 35.2 Gy in 1-daily,
5-weekly fractions of 1.6 Gy followed by a boost to the
posterior fossa to 55.2 Gy in 1-daily, 5-weekly fractions
of 2.0 Gy (in total 32 fractions; RT duration without
interruption 44-46 days).
Table 1 Clinical characteristics of the entire cohort itemized by study/observational patients and treatment era




HIT SIOP PNET 4 era
Trial only
(n Z 176)






Median follow-up time of survivors
(years)
9.3 (0.2-13.9) 9.4 (0.2-13.9) 9.1 (0.3-12.8) 4.7 (0.1-8.0)
Male 141 110 31 98
Female 92 66 26 51
Median age at surgery (years)
(range)
9.3 (4.0-20.8) 9.4 (4.0-20.8) 8.7 (4.2-19.5) 9.7 (4.1-20.9)
Residual tumor
<1.5 cm2 193 150 43 137
1.5 cm2 22 20 2 10
Not documented 18 6 12 2
Histologically defined entity
D/N 31 23 8 21
Classic 193 150 43 115
LC/A 9 3 6 13
Genetically defined entity
WNT-activated 26 23 3 12
SHH-activated (TP53-wt and
mutant)
11 10 1 12
non-WNT/non-SHH, group 3 11 10 1 13
non-WNT/ non-SHH, group 4 50 48 2 22
Not evaluable/not done 135 85 50 90
RT
STRT23.4 Gy 99 85 14 119
HFRT36.0 Gy 84 83 1 0
STRT35.2 Gy 43 7 36 13
Other 7 1 6 1
Not documented 0 0 0 16
Time to RT (days) (range) 33 (11-89) 33 (15-80) 32 (11-89) 32 (16-63)
Duration RT (days) (range) 46 (30-158) 45 (30-79) 46 (37-158) 43 (21-90)
Tumor progressions 51 38 13 29
Deaths 44 32 12 25
Abbreviations: D/N Z desmoplastic medulloblastoma; HFRT Z hyperfractionated RT; LC/A Z large cell/anaplastic medulloblastoma;
RT Z radiation therapy; STRT23.4 Z standard fractionated reduced dose craniospinal RT; STRT35.2 Z standard fractionated high dose
craniospinal RT; WNT Z wingless-related integration site.
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Table 2 Assessment of potential risk factors for PFS according to the Kaplan-Meier method and log rank test
n 7-year PFS (%) 7-year OS (%) PFS P
All patients 382 80.3  3.1% 80.2  2.3
Age at diagnosis
<5 y 23 77.3  8.9 76.2  9.3 .460
5-9 y 190 82.1  2.8 82.7  3.0
10-14 y 102 75.9  4.6 79.8  4.6
>14 y 67 75.1  5.6 74.1  6.4
Sex
Male 239 77.7  2.8 80.1  2.9 .190
Female 143 81.3  3.4 80.4  3.7
HIT SIOP PNET 4 trial participation
HIT SIOP PNET 4 trial patient 176 79.5  3.1 81.0  3.0 .620
Observational patient 206 78.7  3.1 79.2  3.4
Treatment era
During HIT-SIOP PNET 4 trial era 233 79.5  2.7 81.9  2.6 .710
After HIT-SIOP PNET 4 trial era 149 79.4  3.5 79.2  4.0
Treatment era (only STRT23.4)
During HIT-SIOP PNET 4 trial era 99 76.7  4.4 81.2  4.1 .858
After HIT-SIOP PNET 4 trial era 119 79.9  3.8 79.4  4.5
RT protocol
HFRT36 Gy (1) 84 82.6  4.2 82.1  4.3 .797
STRT35.2 Gy (2) 56 79.6  5.5 82.5  5.4 (1) vs (2): .702
STRT23.4 Gy (3) 218 77.8  3.0 79.2  3.2 (1) vs (3): .641
(2) vs (3): .998
RT protocol (only classic/D/N,
residual tumor 1.5 cm2, and time
from surgery to RT <49 d )
STRT35.2 Gy 30 82.4  7.2 85.3  6.8 .952
STRT23.4 Gy 171 81.3  3.0 81.2  3.4
RT protocol (only LC/A)
STRT35.2 Gy 13 84.6  10.0 83.1  11.0 .288
STRT23.4 Gy 5 53.3  24.8 53.3  24.8
Time from surgery to RT start
<49 d 342 80.4  2.2 80.5  2.4 .052
49 d 32 64.6  9.1 73.6  8.8
Duration of RT only STRT 23.4 Gy
49 d 206 78.6  3.0 79.4  3.3 .261
>49 d 12 64.3  14.6 74.1  12.9
Residual tumor
1.5 cm2 330 80.5  2.3 80.8  2.4 .045
>1.5 cm2 32 63.7  8.8 70.6  9.2
Histologically defined entity
Classic (1) 308 81.8  2.3 82.6  2.4 .090
D/N (2) 52 66.7  7.0 70.3  7.2 (1) vs (2): .042
LC/A (3) 22 70.8  10.3 69.5  10.6 (1) vs (3): .263
(2) vs (3): .830
Genetically defined entity
WNT-activated (1) 38 93.2  4.7 91.5  5.8 .092
SHH-activated (TP53-wt and mutant)
(2)
23 73.4  11.1 76.9  11.1 (1) vs (2) .083
non-WNT/non-SHH, group 3 (3) 24 70.8  9.3 67.8  10.4 (1) vs (3): .011
non-WNT/non-SHH, group 4 (4) 72 81.5  4.7 81.6  5.1 (1) vs (4): .161
Abbreviations: D/N Z desmoplastic medulloblastoma; HFRT Z hyperfractionated RT; LC/A Z large cell/anaplastic medulloblastoma;
OSZ overall survival; PFSZ progression-free survival; RTZ radiation therapy; STRT23.4Z standard fractionated reduced dose craniospinal RT;
STRT35.2 Z standard fractionated high dose craniospinal RT; WNT Z wingless-related integration site.
1162 S. Dietzsch et al Advances in Radiation Oncology: NovembereDecember 2020
HIT SIOP PNET 4 trial patients were randomized to
receive STRT23.4 or HFRT.1 If inclusion criteria of the
HIT SIOP PNET 4 trial were not fulfilled, patients were
included in an observational study and received RT
according to individual considerations (STRT35.2 or
STRT23.4). In the post-HIT SIOP PNET 4 era,
STRT35.2 was recommended for patients with large
cell/anaplastic histology and STRT23.4 for all other
patients.
Vincristine during RT and 8 blocks of adjuvant
chemotherapy (cisplatin, lomustine, vincristine) were
administered as previously described.1,16
Genetically defined MB entities
Assignment to MB entities was based on DNA-
methylation profiling or a minimal methylation classifier
and were published previously for subcohorts.4,17-19
Additionally, wingless-related integration site (WNT)-
activation was documented by the demonstration of
nuclear accumulation of b-catenin protein and activating
CTNNB1 mutation also in the absence of further
profiling.4 In contrast to the WHO classification, all
SHH-activated tumors were grouped together
(SHH-activated TP53-wildtype and mutant) because data
on TP53 mutation were not available.12,13
Statistics
Median follow-up time was calculated according to the
method of Schemper and Smith.20 For progression-free
survival (PFS), events were defined as radiographic or
cytologic evidence of progression or relapse, or death of
any cause. For overall survival (OS) death by any cause
was taken into account. Survival times were calculated
from the date of surgery onwards. Time to RT was
defined as interval from first tumor surgery to first day of
RT. The KaplaneMeier method was used to estimate OS
and PFS rates. Survival estimates were compared with the
log rank test. For Cox regression analysis, all factors
associated with P < .1 on univariate analysis were
forwarded to a multivariable analysis without variable
selection. Two separate multivariate Cox regression
models were generated, depending on availability of
molecular data. Associations between variables were
examined using c2 tests. All statistical tests were
considered explorative. Because of the explorative design
and multiple testing we did not define a P value for
significance in the univariate analyses. Results with
P value < .05 in the multivariate models were defined as
significant. All analyses were performed using the
Statistical Package for Social Sciences, version 24
(SPSS Inc, Chicago, IL).
Results
Patients’ characteristics
Characteristics of the 382 eligible patients treated in 63
institutions are provided in Figure 1 and Table 1. One
hundred seventy-six patients (46.1%) participated in the
international HIT SIOP PNET 4 trial.1,21 All patients
underwent initial surgery. A second surgery before RT
was performed in 17/382 (4.5%) patients. Median age was
9.4 years (range, 4.0-20.9 years).
Median follow-up time in the present study was 7.3
(range, 0.09-13.86) years for all patients and 9.4 (range,
0.22-13.86) years for the HIT SIOP PNET 4 patients.
Eighty patients (20.9%) showed disease progression or
relapse, and 69 patients died (18.1%). PFS rates at 3, 5,
and 7 years was 83.9%  1.9%, 80.3%  2.1%, and
79.0%  2.2%. The corresponding OS rates were 91.4%
 1.5%, 86.5%  1.8%, and 80.2%  2.3%.
Effect of participation in the randomized HIT SIOP
PNET 4 trial
There was no difference between HIT SIOP PNET 4
trial patients and observational patients outside the
randomized trial (7 years PFS 79.5%  3.1% vs
78.7%  3.1%; PZ .62; Table 2; Fig 2A,B). To evaluate
potential biases due to different treatment eras or RT
protocols, we compared patients treated during versus
after the HIT SIOP PNET 4 trial recruitment era and
found no differences in PFS, either for the whole
cohort (79.5%  2.7% vs 79.4%  3.5%; P Z .710) or
for the subgroup of patients treated with STRT23.4 Gy
(76.7%  4.4% vs 79.9%  3.8%; P Z .858).
Analyses of prognostic factors in MB
Results of univariate comparisons of multiple potential
prognostic factors are presented in Table 2. Subsequent
multivariate analyses were done including all factors with
P < .1 in the univariate analyses (histologically/
genetically defined entity, residual tumor, time from
surgery to RT start) and in 2 separate cohorts based on the
availability of genetic annotation data (Table 3). These
factors were identified as of interest:
Time from surgery to RT start
Time to RT was known in 374 patients (97.9%). The
median time to RT was 32 days (range, 11-89 days). The
protocol defined start of RT within 29 days postsurgery,
which was achieved in 120/374 patients (32.1%).
Thirty-two patients (8.6%) started RT 49 days
after surgery or later. Time to RT  49 days showed a
trend for worse PFS in univariate testing (64.6%  9.1%
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vs 80.4%  2.2%; PZ .052, Fig 2C). However, it was an
independent risk factor on PFS in both cohorts
of the multivariate analysis (hazard ratio [HR], 2.01;
P Z .012/HR, 3.46; P Z .018).
Duration of RT
The duration of RT ranged between 21 and 158 days
(median, 44 days). The proportion of patients with
duration of RT > 49 days varied between the different
treatment protocols and was 5.5% (STRT23.4), 19.6%
(STRT35.2), and 40.5% (HFRT) (c2 P < .01). Duration
of RT ( 49 days vs > 49 days) had no effect on PFS
for the whole cohort (78.9%  2.4% vs 78.8%  5.5%;
P Z .931). A trend for inferior PFS for RT duration
> 49 days was seen when analysis was restricted to
patients with STRT23.4 7-year PFS (64.3% vs 78.6%;
PZ .261). However, protracted RT was only given in 12
patients.
Residual tumor ‡1.5cm2
Central review of the postoperative MR imaging was
available in 364 cases (95.3%). Complete tumor resection
or residual tumor <1.5 cm2 was achieved in 330 of 362
patients (91.2%). In 20 patients, the extent of resection
could not be assessed. Postoperative residual tumor
influenced PFS in the univariate analysis (80.5%  2.3%
vs 63.7%  8.8%; P Z .045), but the extent of resection
was not maintained as an independent risk factor on
multivariate analysis (P Z .061/P Z .078).
Histologically defined tumor entity
Central histologic review revealed classic MB (classic)
in 308 (80.6%), desmoplastic MB (D/N) in 52 (13.6%),
and large cell/anaplastic MB (LC/A) in 22 cases (5.8%).
Univariate group comparisons of the histologically
defined entities showed different PFS between classic and
D/N (81.8%  2.3% vs 66.7%  7.0%; P Z .042).
Classic histology versus D/N remained an influencing
factor on PFS in cohort 2 (n Z 355) of the multivariate
analyses but lost its effect after adjustment for additional
genetical annotation (cohort 1, n Z 147).
We additionally evaluated the effect of RT strategy in
LC/A. With todayés risk stratification, LC/As are
considered high-risk and usually not eligible for an
STRT23.4 strategy. Among the 22 patients with LC/A,
the 5 patients treated with reduced dose CSI 23.4 Gy had
a trend for poorer PFS than those treated with STRT35.2
(53.3%  24.8% vs 84.6%  10.0%; P Z .288).
Interestingly, there were 2 patients with WNT-activated
MB among patients with LC/A MB (1 STRT23.4,
1 HFRT). Both were free of an event after more than
10 years of follow-up.
Genetically defined tumor entity
Results of subsequent molecular/epigenetic analyses
were available for 157 patients (41.1%). Non- WNT/
non-SHH MBs, found in 56.4% (with subgroups: group 4,
45.9%; group 3, 15.3%), were most frequent, followed by
WNT-activated (24.2%) and SHH-activated tumors
Table 3 Multivariate analysis of risk factors for PFS: Two multivariable regression analyses were done, 1 for all patients but not
considering genetically defined MB entity (cohort 2) and 1 considering only patients with genetical annotation (cohort 1)
Cohort 1 (n Z 147) Cohort 2 (355)
Factors included: Histology, residual
tumor, time from surgery to RT start,
genetically defined entity
Factors included: Histology, residual
tumor, time from surgery to RT start
Category n Hazard ratio 95% CI P n Hazard ratio 95% CI P
Histologically defined entity
Classic 117 Ref. 286 Ref.
D/N 24 1.00 0.25-4.02 .996 48 2.01 1.12-3.60 .019
LC/A 6 0.96 0.12-7.57 .971 21 1.95 0.83-4.58 .125
Residual tumor
1.5 cm2 137 Ref. 325 Ref.
>1.5 cm2 10 2.69 0.90-8.08 .078 30 1.89 0.97-3.69 .061
Time from surgery to RT start
<49 d 132 Ref. 323 Ref.
49 15 3.460 1.31-9.11 .012 32 2.208 1.15-4.26 .018
Genetically defined entity
WNT-activated 35 Ref. Data not available
SHH-activated (TP53-wt and mutant) 21 4.76 0.73-31.20 .104
non-WNT/non-SHH, group 3 23 5.49 1.42-21.24 .014
non-WNT/non-SHH, group 4 68 2.213 0.61-8.01 .226
Abbreviations: CI Z confidence interval; D/N Z desmoplastic medulloblastoma; LC/A Z large cell/anaplastic medulloblastoma; MB Z medul-
loblastoma; PFS Z progression-free survival; RT Z radiation therapy; WNT Z wingless-related integration site.
Significant differences are printed in bold.
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(14.6%). Univariate comparisons of the different
molecular/epigenetic subgroups revealed differences in
PFS between WNT-activated and non-WNT/non-SHH,
group 3 (93.2%  4.7% vs 70.8%  9.3%; P Z .011;
Fig 2E,F) This difference was also maintained in the
multivariate analysis (HR, 5.49; P Z .014).
We additionally evaluated the subgroup of
WNT-activated MBs (n Z 38; 25 STRT23.4, 3
STRT35.2, 8 HFRT, 2 RT regimen not documented).
The only 2 relapses occurred among patients who did
not fulfill inclusion criteria for the current SIOP PNET
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Figure 2 Kaplan-Meier plots of progression free survival (PFS) and overall survival (OS): (A) PFS and (B) OS of patients treated
within (trial patients) versus outside (observational patients) the HIT‑SIOP PNET 4 trial. (C) PFS and (D) OS according to time from
surgery to start of radiation therapy (RT) < 49 days versus  49 days. (E) PFS and (F) OS according to genetically defined entity
(all SHH-activated tumors were grouped together [SHH-activated TP53-wildtype and mutant] because data on TP53 mutation were not
available).
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tumor > 1.5 cm2; RT start  40 days after surgery).
One patient was 16 years old, had residual tumor > 1.5
cm2 and started RT at day 57 after surgery. The second
patient started RT at day 54 after surgery. None of the
18 patients who would have fulfilled inclusion criteria
of the low risk arm showed progressive disease, but 2
patients developed secondary malignancies (1 mela-
noma and 1 glioblastoma) 8.2 and 8.6 years after
diagnosis, respectively. Patients, who were potentially
suitable for the low risk arm had a 7 years PFS and OS
of 100% as compared with 80.5  4.8 (P Z .174) and
78.1  5.6 (P Z .216) for patients, who fulfilled the
criteria of the standard risk arm (n Z 77, non-WNT/
non-SHH [group 3/4] or SHH-activated tumors
[no data on TP53 mutational status], no residual tumor
> 1.5 cm2; RT start 40 days after surgery).
Discussion
In the present analysis we assessed patient
characteristics, treatment, outcome, and possible risk
factors of a large cohort of nonmetastatic MB in children
and adolescents. Approximately half of the patients were
enrolled into the European HIT SIOP PNET 4 trial.
Outcome was reported previously, however, with a
shorter follow-up.1 Results matched those of previous
prospective randomized studies. In 2009, von Hoff et al
published the long-term outcome of patients treated in the
multicenter trial HIT’91. The 10-year event-free survival
(EFS) and OS rates of all 114 M0-patients were 65  5
and 73%  4%, respectively. The 45 patients with M0
and maintenance chemotherapy had a 10-year EFS and
OS of 83  6 and 91%  4%, respectively.22
Effect of treatment under protocol conditions
Our primary purpose was to evaluate the effect of
“on-protocol” treatment. There is a widespread belief that
inclusion in clinical trials offers the best treatment and
outcome. A “trial effect” on outcome has not been
generally proven so far. In pediatric studies, however,
positive effects were apparently seen.23 Centrally
reviewed staging played an important role. In the
Children's Oncology Group (COG) A9961 study of
Packer et al, central neuroradiographic review revealed
that 30 of 409 reviewed patients had evidence of residual
or metastatic disease. In retrospect, the latter were
inappropriately assigned to the study with disseminated
disease. This cohort had a significantly worse EFS than
the fully assessable patients (P < .005).16 In our cohort,
HIT SIOP PNET 4 trial participants and observational
patients, as well as patients in the HIT SIOP PNET 4 era
and patients in the era after closure of the HIT SIOP
PNET 4 trial, had identical regulations for staging and
central review and were treated according to central
disease stratification. No difference in PFS and OS were
found between the on and off protocol cohorts. To
evaluate potential biases due to different treatment eras
and treatment protocols we performed further subgroup
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centralized review program for prospective trials
produced equivalent outcome for patients within and
outside a randomized trial. However, we had no control
group of patients without a central review program.
Therefore, we cannot quantify the benefit compared with
patients without central review. In contrast to the COG
A9961 trial, all patients who were ineligible were
identified before start of treatment and allocated to
the corresponding treatment protocols of the HIT 2000
trial.16
Effect of time factors
The detrimental effect of delayed RT is continuously a
matter of debate. Kann et al demonstrated worse outcome
when RT started more than 90 day after surgery.6 Other
retrospective analysis with different cut-offs between 21
and 42 days failed to prove an effect.7,24,25 In the national
database analysis of Chin et al, delaying RT more than 35
days but not more than 90 days was not associated with
inferior outcome. But the time scale of 35 to 90 days was
not further subdivided or continuously evaluated.8 By
contrast, the HIT SIOP PNET 4 patients, in whom RT
started with a delay of 49 days or more, had a 5-year EFS
of 67% compared with 81% when RT started within 48
days (PZ .04).1 In our study, a 7-year PFS of 64.6% was
seen in patients starting RT after 49 days versus 80.4%
(P Z .052 in univariate analysis). These findings were
confirmed by multivariate Cox regression analyses in all
models, including the presence of molecular subgrouping
data (P Z .012, P Z .018). An effect of time interval to
RT was also proven as a continuous category in the HIT
SIOP PNET 4 trial. Timely initiation of RT is therefore
important for patient outcome and a prolonged time-to-
RT should be avoided.
In the SIOP-UKCCSG-PNET 3, in which a STRT35.2
RT schedule was used, there was a better EFS for patients
completing RT within 50 days compared with those
taking more than 50 days (3-year EFS of 78.5% vs 53.7%;
P Z .0092).9 A negative effect of protracted RT on PFS
or local control was also demonstrated in other
retrospective analyses.7,25 In the HIT SIOP PNET 4 trial,
an effect of duration of RT on EFS could not be
demonstrated.1 In our analysis, no difference in PFS
between both groups was seen for the whole cohort
(PZ .931). Because of the different number of days with
RT between the 3 schedules and the resulting different RT
durations (STRT23.4, 40-42 days; STRT35.2, 44-46
days; HFRT, 46-48 days), a second analysis was done
with STRT23.4-patients only. A trend for inferior PFS for
RT duration > 49 days (7-year PFS 64.3% vs 78.6%;
P Z .261) was seen in this cohort. The statistical
observation is, however, of limited value, because a
protracted RT was given in only 12 patients.
Effect of residual tumor
In univariate analysis we could confirm the findings of
HIT SIOP PNET 4 and Children's Cancer Group (CCG)
921 trials for residual disease above 1.5 cm2.1,5 They had
a 7-year PFS of 63.7% compared with 80.5% achieved in
patients with minor or no residual disease (PZ .045). On
multivariate analysis, some of this effect was attributed to
confounding factors (P Z .061). However, when
interpreting these findings together with published data,
the assumption of a negative effect of postoperative
residual tumor in patients with nonmetastatic MB can be
supported.
Histologically defined tumor entity
On univariate analysis, the presence of D/N had a
prognostic negative effect on outcome for patients in
whom no data for genetic annotation to MB entities were
available. Because most D/N relate to SHH-activated MB,
this might be explained by the presence of SHH/
TP53-mutant MBs with worse prognosis in these cases.26
Significantly worse outcome of LC/A MB was seen in the
COG A9961 study (OS 75% vs 89%) and in a subcohort
of patients of The International Society of Pediatric
Oncology - United Kingdom Children’s Cancer Study
Group - PNET 3 (SIOP-UKCCSG-PNET 3) trial.9,16,27 In
a larger cohort of patients, including infants, in the
preceding HIT’91 trial, LC/A MB was a significant
negative prognostic factor.28 In the HIT SIOP PNET 4
trial patients with LC/A were excluded after 2003.
Therefore, only 16 patients with LC/A MB were analyzed
and showed a nonsignificant inferior outcome compared
with patients with non-LC/A MB (7-year EFS 64.0% vs
80%; P Z .21).1 Patients of our cohort treated with
conventional fractionated full dose CSI (STRT35.2 Gy)
achieved a 7-year PFS of 84.6% and 7-year OS of 83.1%,
respectively, suggesting a higher craniospinal dose for
patients with LC/A. Only 2 patients with WNT-MB had
an LC/A (no relapse occurred).
Genetically defined tumor entity
The annotation to genetically defined MB entities
confirmed the prognostic importance of the genetic MB
classification according to WHO 2016, with best outcome
for WNT-activated tumors and worst prognosis of
non-WNT/non-SHH group 3.29-31 Because of the small
number of patients, no conclusions can be made as to
whether the trend for worse PFS of non-WNT/non-SHH
group 3 compared with group 4 confirms the different
outcomes of these groups as described by Schwalbe et al
or if an equal outcome can be expected like in the HIT
SIOP PNET 4 cohort.31,32 Worst prognosis of all groups
could also be expected in the SHH-activated TP53 mutant
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MB, but this group could not be identified because of
lacking TP53-mutational analysis.26 The 7-year PFS and
OS of WNT patients were 93.2% and 91.5%,
respectively, in our cohort, and confirm the subgroup
analyses of the HIT SIOP PNET 4 trial.4,32 This result
matches also with other patient cohorts even in metastatic
disease.29,31,33,34 The potential for reduction of treatment
intensity, including a reduced dose of 18 Gy CSI, in this
cohort is presently under evaluation. (eg, SIOP PNET 5
trial). However, reduction of CSI dose has to be done with
caution. The results of the COG ACNS0331 showed
worse PFS after 18 Gy CSI but without biologically
defined risk stratification.35
Conclusions
The results of this study reflect treatment and outcome
of patients with nonmetastatic MB > 4 years in 63
participating centers of German-speaking countries during
the HIT 2000 era between 2000 and 2011. OS and PFS
rates were high even outside a randomized clinical (HIT
SIOP PNET 4) trial but with identical quality control
procedures. We interpret this as a result of consequent
management standards, including central review of
imaging and pathology as well as central individualized
treatment recommendations. Nevertheless, inclusion into
prospective clinical trials is strongly encouraged to
achieve further refinement of biological stratification and
disease management with the aim of improving outcome.
Time to RT was an important predictor of survival,
suggesting a timely initiation of RT.
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